摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-(2-羟基-5-甲基苯基)-丙-1-烯 | 65490-14-4

中文名称
2-(2-羟基-5-甲基苯基)-丙-1-烯
中文别名
——
英文名称
2-isopropenyl-4-methylphenol
英文别名
4-methyl-2-(prop-1-en-2-yl)phenol;4-Methyl-2-prop-1-en-2-ylphenol
2-(2-羟基-5-甲基苯基)-丙-1-烯化学式
CAS
65490-14-4
化学式
C10H12O
mdl
——
分子量
148.205
InChiKey
FAYMTZBWUJYBPN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    222-224 °C
  • 密度:
    1.012 g/cm3(Temp: 24 °C)

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    11
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.2
  • 拓扑面积:
    20.2
  • 氢给体数:
    1
  • 氢受体数:
    1

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-(2-羟基-5-甲基苯基)-丙-1-烯氢气 、 palladium diacetate 作用下, 以 甲醇 为溶剂, 以42.6 g的产率得到4-甲基-2-(1-甲乙基)苯酚
    参考文献:
    名称:
    一种药用级麝香草酚特定杂质的制备方法
    摘要:
    本申请公开了一种药用级麝香草酚特定杂质的制备方法,涉及制药领域。药用级麝香草酚特定杂质的制备方法包括:对甲酚和乙酰乙酸乙酯在无溶剂下、酸催化缩合反应得到4,6‑二甲基‑2H‑1‑苯并吡喃‑2‑酮,再通过碱化脱羧反应得到4‑甲基‑2(丙‑1‑烯‑2‑基)苯酚,再通过氢化反应得到所述药用级麝香草酚特定杂质4‑甲基‑2‑(1‑甲乙基)苯酚。本申请提供的药用级麝香草酚特定杂质的制备方法,产品纯度高,合成工艺简单,收率高。该杂质可用于药用级麝香草酚杂质研究,也可作为麝香草酚衍生物产品制备研究。
    公开号:
    CN117024253A
  • 作为产物:
    描述:
    alkaline earth salt of/the/ methylsulfuric acid 生成 2-(2-羟基-5-甲基苯基)-丙-1-烯
    参考文献:
    名称:
    Fries; Fickewirth, Chemische Berichte, 1908, vol. 41, p. 372
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Recyclable Selective Palladium-Catalyzed Synthesis of Five-, Six- or Seven-Membered Ring Lactones and Lactams by Cyclocarbonylation in Ionic Liquids
    作者:Fangguo Ye、Howard Alper
    DOI:10.1002/adsc.200606100
    日期:2006.9
    ionic liquids, BMIM PF6 or BMIM NTf2, are used successfully for the palladium-catalyzed cyclocarbonylation of 2-allylphenols and anilines, 2-vinylphenols, and 2-aminostyrenes. The reaction proceeds cleanly and efficiently to afford high yields of lactones or lactams with good or excellent selectivity for one isomer. The ionic liquid containing the palladium catalyst, and ligand, is recyclable in all cases
    离子液体BMIM PF 6或BMIM NTf 2已成功用于2-烯丙基苯酚和苯胺,2-乙烯基苯酚和2-氨基苯乙烯的钯催化环羰基化。反应干净,有效地进行,以高产率获得内酯或内酰胺,并且对一种异构体具有良好或优异的选择性。包含钯催化剂和配体的离子液体在所有情况下都是可回收的。
  • Rhodium(<scp>iii</scp>)-catalyzed [5+1] annulation of 2-alkenylphenols with maleimides: access to highly functionalized spirocyclic skeletons
    作者:Anil Kumar、Kandikere Ramaiah Prabhu
    DOI:10.1039/d1cc01758f
    日期:——
    A new edition of [5+1] annulation reaction of maleimides with 2-alkenylphenols has been discovered under a Rh(III)-catalytic system. The process leads to an efficient synthesis of valued spirocyclic scaffolds bearing an oxygen-containing spiro carbon in a single step and shows a broad substrate scope with good functional group tolerance. The synthetic utility has been exemplified by synthesizing highly
    在Rh( III )-催化体系下发现了马来酰亚胺与2-烯基苯酚的[5+1]环化反应的新版本。该过程导致在单个步骤中有效合成带有含氧螺碳的有价值的螺环支架,并显示出具有良好官能团耐受性的广泛底物范围。合成效用已通过合成高度官能化的 2,2-二取代-2 H-色烯骨架和低催化剂负载的克级合成来举例说明。
  • Merging Chiral Brønsted Acid/Base Catalysis: An Enantioselective [4 + 2] Cycloaddition of <i>o</i>-Hydroxystyrenes with Azlactones
    作者:Yu-Chen Zhang、Qiu-Ning Zhu、Xue Yang、Lu-Jia Zhou、Feng Shi
    DOI:10.1021/acs.joc.6b00078
    日期:2016.2.19
    An enantioselective [4 + 2] cycloaddition of o-hydroxylstyrenes with azlactones has been established by merging chiral Brønsted acid (chiral phosphoric acid) and base (chiral guanidine) catalysis, which constructed a biologically important dihydrocoumarin scaffold in an efficient and enantioselective style (up to 99% yield, 96:4 er). This approach has not only realized the successful application of
    通过合并手性布朗斯台德酸(手性磷酸)和碱(手性胍)催化,建立了邻羟基苯乙烯与对映体的对映选择性[4 + 2]环加成反应,从而以有效和对映选择性的方式构建了生物学上重要的二氢香豆素骨架。至99%的收率(96:4 er)。该方法不仅实现了邻羟基苯乙烯作为氧杂二烯前体在催化不对称环加成反应中的成功应用,而且建立了一种新的手性磷酸和手性胍的协同催化体系。
  • Identification of Chlamydia pneumoniae DNA in Carotid Plaques
    作者:Fabio Chierichetti、Eloise Arbustini、Vittorio Arici、Shahdeh Parsapour Moghadam、Barbara Conti、Attilia Bagliani
    DOI:10.1177/000331970005101004
    日期:2000.10
    Chlamydia pneumoniae (CP) is a bacterium that in recent years has been investigated as an etiologic agent for atherosclerosis. It is a ubiquitous microorganism that has been isolated in various regions of the vascular system and its prevalence is about 10% in the patient population. This study involved a group of 43 patients (27 men, 16 women, mean age 68 years) who underwent carotid endarterectomy
    肺炎衣原体(CP)是一种细菌,近年来已被研究为动脉粥样硬化的病原体。它是一种普遍存在的微生物,已在血管系统的各个区域分离出来,其患病率在患者人群中约为10%。这项研究涉及一组43例接受了颈动脉内膜切除术的患者(27例男性,16例女性,平均年龄68岁)。约9.3%的患者产生的斑块对肺炎衣原体的DNA基因组呈阳性。
  • Role of Activated Protein C Resistance in Left Atrial Thrombogenesis in Patients with Mitral Stenosis
    作者:Ismet Hisar、Mehmet Ileri、Ertan Yetkin、Ramazan Atak、Kubilay Senen、Feridun Kosar、Semra Dundar、Deniz Demirkan
    DOI:10.1177/000331970005101008
    日期:2000.10

    Activated protein C resistance (APC-R) is the most common inherited cause of clinically apparent venous thromboembolism. Previous data indicate that left atrial thrombus (LAT) formation is a common complication in mitral stenosis (MS) and a hypercoagulable state exists in these patients. The aim of this study was to invastigate the association between APC-R and LAT formation in patients with MS. Seventy-seven consecutive patients with rheumatic MS were included in this study. Transesophageal echocardiography was performed on all patients to assess the presence of any thrombus or spontaneous echo contrast (LASEC) in the left atrial cavity or appendage. Thirty four of the patients had LAT and 43 did not. Prevelance of APC-R was smiliar between the two groups of patients with and without LAT (23% vs 16%, p=0.425). LAT(+) patients had higher incidence of atrial fibrillation (AF, 74% vs 51%, p=0.046) and LASEC (71% vs 19%, p<0.001) compared to LAT(-) patients. On multivariate regression analysis, only the presence of LASEC achieved statistical significance as an independent risk factor for LAT formation (p=0.0001, odds ratio=9.589, 95% confidence interval [CI] =3.143-29.251). Because on (continued on next page) univariate analysis both LASEC and AF were associated with LAT, we also compared the prevelance of APC-R in the subgroups of patients who have these risk factors with and without LAT. There was a correlation between the presence of APC-R and LAT in the AF(+) subgroup of MS patients (p=0.033, odds ratio=8.167, 95% CI=1.001-72.812). However, the presence of APC-R was not associated with the increased risk of LAT in LASEC(+) patients (p=0.217, odds ratio =1.200, 95% CI=1.003-1.435). Although the presence of APC-R itself is not an independent risk factor for LAT formation in MS, it may increase the risk of LAT when present in combination with AF (as an additional risk factor) in these patients.

    激活蛋白C抵抗(APC-R)是临床明显的静脉血栓栓塞最常见的遗传性原因。先前的数据表明,左心房血栓(LAT)形成是二尖瓣狭窄(MS)的常见并发症,并且这些患者存在高凝状态。本研究旨在调查APC-R与MS患者中LAT形成之间的关联。本研究纳入了77例风湿性MS连续患者。对所有患者进行食管超声心动图检查,评估左心房腔或心耳中是否存在任何血栓或自发性回声对比(LASEC)。其中34例患者有LAT,43例没有。两组患者中APC-R的患病率相似(23% vs 16%,p=0.425)。LAT(+)患者与LAT(-)患者相比,房颤(AF)发生率更高(74% vs 51%,p=0.046),LASEC发生率更高(71% vs 19%,p<0.001)。多元回归分析显示,只有LASEC的存在在LAT形成中达到统计学意义上的独立风险因素(p=0.0001,比值比=9.589,95%置信区间[CI]=3.143-29.251)。因为在单变量分析中,LASEC和AF都与LAT相关,我们还比较了这些风险因素存在与不存在的子组中APC-R的患病率。在MS患者的AF(+)亚组中,APC-R的存在与LAT之间存在相关性(p=0.033,比值比=8.167,95% CI=1.001-72.812)。然而,在LASEC(+)患者中,APC-R的存在与LAT增加风险无关(p=0.217,比值比=1.200,95% CI=1.003-1.435)。尽管APC-R的存在本身不是MS中LAT形成的独立风险因素,但当与AF(作为额外风险因素)结合存在时,可能会增加这些患者LAT的风险。
查看更多

同类化合物

(βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-盐酸沙丁胺醇 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (R)富马酸托特罗定 (R)-(-)-盐酸尼古地平 (R)-(+)-7-双(3,5-二叔丁基苯基)膦基7''-[((6-甲基吡啶-2-基甲基)氨基]-2,2'',3,3''-四氢-1,1''-螺双茚满 (R)-3-(叔丁基)-4-(2,6-二苯氧基苯基)-2,3-二氢苯并[d][1,3]氧杂磷杂环戊烯 (R)-2-[((二苯基膦基)甲基]吡咯烷 (N-(4-甲氧基苯基)-N-甲基-3-(1-哌啶基)丙-2-烯酰胺) (5-溴-2-羟基苯基)-4-氯苯甲酮 (5-溴-2-氯苯基)(4-羟基苯基)甲酮 (5-氧代-3-苯基-2,5-二氢-1,2,3,4-oxatriazol-3-鎓) (4S,5R)-4-甲基-5-苯基-1,2,3-氧代噻唑烷-2,2-二氧化物-3-羧酸叔丁酯 (4-溴苯基)-[2-氟-4-[6-[甲基(丙-2-烯基)氨基]己氧基]苯基]甲酮 (4-丁氧基苯甲基)三苯基溴化磷 (3aR,8aR)-(-)-4,4,8,8-四(3,5-二甲基苯基)四氢-2,2-二甲基-6-苯基-1,3-二氧戊环[4,5-e]二恶唑磷 (2Z)-3-[[(4-氯苯基)氨基]-2-氰基丙烯酸乙酯 (2S,3S,5S)-5-(叔丁氧基甲酰氨基)-2-(N-5-噻唑基-甲氧羰基)氨基-1,6-二苯基-3-羟基己烷 (2S,2''S,3S,3''S)-3,3''-二叔丁基-4,4''-双(2,6-二甲氧基苯基)-2,2'',3,3''-四氢-2,2''-联苯并[d][1,3]氧杂磷杂戊环 (2S)-(-)-2-{[[[[3,5-双(氟代甲基)苯基]氨基]硫代甲基]氨基}-N-(二苯基甲基)-N,3,3-三甲基丁酰胺 (2S)-2-[[[[[[((1R,2R)-2-氨基环己基]氨基]硫代甲基]氨基]-N-(二苯甲基)-N,3,3-三甲基丁酰胺 (2-硝基苯基)磷酸三酰胺 (2,6-二氯苯基)乙酰氯 (2,3-二甲氧基-5-甲基苯基)硼酸 (1S,2S,3S,5S)-5-叠氮基-3-(苯基甲氧基)-2-[(苯基甲氧基)甲基]环戊醇 (1-(4-氟苯基)环丙基)甲胺盐酸盐 (1-(3-溴苯基)环丁基)甲胺盐酸盐 (1-(2-氯苯基)环丁基)甲胺盐酸盐 (1-(2-氟苯基)环丙基)甲胺盐酸盐 (-)-去甲基西布曲明 龙胆酸钠 龙胆酸叔丁酯 龙胆酸 龙胆紫 龙胆紫 齐达帕胺 齐诺康唑 齐洛呋胺 齐墩果-12-烯[2,3-c][1,2,5]恶二唑-28-酸苯甲酯 齐培丙醇 齐咪苯 齐仑太尔 黑染料 黄酮,5-氨基-6-羟基-(5CI) 黄酮,6-氨基-3-羟基-(6CI) 黄蜡,合成物 黄草灵钾盐